<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061397</url>
  </required_header>
  <id_info>
    <org_study_id>The SOS Trial</org_study_id>
    <nct_id>NCT02061397</nct_id>
  </id_info>
  <brief_title>Safety of Simvastatin in LAM and TSC</brief_title>
  <acronym>SOS</acronym>
  <official_title>The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The LAM Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if simvastatin can be taken safely in patients&#xD;
      with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is&#xD;
      the first step in looking at simvastatin as a drug that may help patients, by impacting the&#xD;
      growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC&#xD;
      patients. The study also seeks to learn more about how simvastatin works, when given to&#xD;
      patients being treated with everolimus or sirolimus, and to evaluate the safety and any&#xD;
      potential benefit to patients taking this 2-drug combination.&#xD;
&#xD;
      The primary objective of this study is to determine the safety of simvastatin in the&#xD;
      treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of&#xD;
      sirolimus or everolimus.&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
        -  To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1).&#xD;
&#xD;
        -  To assess the effect of simvastatin on forced vital capacity (FVC).&#xD;
&#xD;
        -  To assess the effect of simvastatin on diffusing lung capacity (DLCO).&#xD;
&#xD;
        -  To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D)&#xD;
           serum levels.&#xD;
&#xD;
        -  To assess the effect of simvastatin with questionnaire- based assessments of dyspnea,&#xD;
           fatigue, and quality of life (QOL).&#xD;
&#xD;
        -  Assess signs of clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing written informed consent, study related tests/procedures will be done to&#xD;
      ensure eligibility for the study. If found to be eligible, the participant will be given&#xD;
      simvastatin at a starting dose of 20 mg, to be taken each evening by mouth. If after 2 months&#xD;
      the simvastatin 20 mg dose is tolerated, the dose of simvastatin will be increased to 40 mg&#xD;
      each evening by mouth. Doses may be adjusted as needed, should the participant experience&#xD;
      side effects from simvastatin. The participant's dose of everolimus or sirolimus is not&#xD;
      expected to change, as this is a dose that has been previously tolerated. If side effects&#xD;
      occur as a result of the combination of drugs, the dosages may be adjusted by the study&#xD;
      physician (investigator).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients</measure>
    <time_frame>5 months</time_frame>
    <description>Safety is a primary outcome measure which will be assessed by any major changes or deterioration in patient health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Predicted FEV1</measure>
    <time_frame>5 months</time_frame>
    <description>Lung function will be measured by FEV1: forced expiratory volume in 1s mean and calculated as % predicted +_ SD (standard deviation).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Lymphangioleiomyomatosis</condition>
  <condition>Tuberous Sclerosis Complex</condition>
  <arm_group>
    <arm_group_label>simvastatin treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
    <arm_group_label>simvastatin treatment arm</arm_group_label>
    <other_name>trade name Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus Oral Product</intervention_name>
    <description>Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
    <arm_group_label>simvastatin treatment arm</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus Oral Product</intervention_name>
    <description>Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
    <arm_group_label>simvastatin treatment arm</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, age 18 and older with clinically definitive diagnosis (biopsy proven or&#xD;
             compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS&#xD;
             (LAM-TS).&#xD;
&#xD;
          -  Treated with a stable (at least 3 months) dose of sirolimus or everolimus&#xD;
&#xD;
          -  Negative pregnancy test (women of child bearing potential) at screening.&#xD;
&#xD;
          -  Women of childbearing potential must be using barrier, medically acceptable&#xD;
             contraceptive precautions.&#xD;
&#xD;
          -  Signed and dated informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Known allergy to simvastatin or currently taking simvastatin, or therapy with a&#xD;
             medication in the same class as simvastatin within the past 30 days.&#xD;
&#xD;
          -  Allergy to sirolimus or everolimus.&#xD;
&#xD;
          -  Current use of other than sirolimus or everolimus investigational drug for TSC or LAM&#xD;
             within the past 30 days.&#xD;
&#xD;
          -  Use of estrogen containing medications, including birth control pills, within the 30&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  Treatment with drugs having known metabolic interactions with statin drugs (e.g.&#xD;
             cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole,&#xD;
             erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin,&#xD;
             warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil,&#xD;
             cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine,&#xD;
             and ranolazine.&#xD;
&#xD;
          -  Participation in another clinical study(ies) of an investigational treatment or drug&#xD;
             within 30 days prior to the screening visit.&#xD;
&#xD;
          -  Amiodarone; within the past 30 days.&#xD;
&#xD;
          -  Significant dysfunction of liver (ALT &gt; 2 times upper limit of normal-ULN), kidney&#xD;
             (serum creatinine &gt; 1.5 times ULN), or blood (leucopenia (ANC&lt;2000), anemia, Hgb &lt; 11&#xD;
             gm/dl).&#xD;
&#xD;
          -  History of inflammatory muscle disease or myopathy.&#xD;
&#xD;
          -  Bleeding diathesis or anticoagulant therapy.&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia or diabetes.&#xD;
&#xD;
          -  Pregnant, breast feeding, or plan to become pregnant within the next 6 months&#xD;
&#xD;
          -  Inadequate contraception (must agree to barrier method)&#xD;
&#xD;
          -  History of organ transplant.&#xD;
&#xD;
          -  Active on transplant list.&#xD;
&#xD;
          -  Severe or uncontrolled medical conditions which would cause an unacceptable safety&#xD;
             risk or compromise compliance with the protocol.&#xD;
&#xD;
          -  Unstable seizures (recent changes in pattern or anti-epileptics).&#xD;
&#xD;
          -  Mental illness or cognitive deficit precluding informed consent..&#xD;
&#xD;
          -  Inability to attend scheduled clinic visits or comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera P Krymskaya, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryl Kreider, MD, MSCE</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank McCormack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol. 2012 May;46(5):563-5. doi: 10.1165/rcmb.2011-0381ED.</citation>
    <PMID>22550272</PMID>
  </reference>
  <reference>
    <citation>Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.</citation>
    <PMID>23035046</PMID>
  </reference>
  <reference>
    <citation>Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.</citation>
    <PMID>23947572</PMID>
  </reference>
  <results_reference>
    <citation>Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11.</citation>
    <PMID>21482669</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <results_first_submitted>July 1, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphangioleiomyomatosis (LAM)</keyword>
  <keyword>tuberous sclerosis complex (TSC)</keyword>
  <keyword>simvastatin</keyword>
  <keyword>sirolimus</keyword>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02061397/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02061397/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Simvastatin Treatment Arm</title>
          <description>Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months&#xD;
Simvastatin: Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Simvastatin 20 mg Oral Daily for 2 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Simvastatin 40 mg Oral Daily for 2 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Simvastatin Treatment Arm</title>
          <description>Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months&#xD;
Simvastatin: Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rate of change in FEV1</title>
          <description>The baseline measure was lung function accessed as the forced expiratory volumes (unit ml) in 1 second (FEV1) response and was calculated as the rate of change in FEV1, which was calculated as percentage of predicted.</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients</title>
        <description>Safety is a primary outcome measure which will be assessed by any major changes or deterioration in patient health.</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Simvastatin Treatment Arm</title>
            <description>Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months&#xD;
Simvastatin: Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients</title>
          <description>Safety is a primary outcome measure which will be assessed by any major changes or deterioration in patient health.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Predicted FEV1</title>
        <description>Lung function will be measured by FEV1: forced expiratory volume in 1s mean and calculated as % predicted +_ SD (standard deviation).</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Simvastatin Treatment Arm</title>
            <description>Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months&#xD;
Simvastatin: Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FEV1</title>
          <description>Lung function will be measured by FEV1: forced expiratory volume in 1s mean and calculated as % predicted +_ SD (standard deviation).</description>
          <units>percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Simvastatin Treatment Arm</title>
          <description>Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months&#xD;
Simvastatin: Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral adema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vera Krymskaya</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-9861</phone>
      <email>krymskay@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

